Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The effects of coenzyme Q10 on women with breast cancer: a systematic review protocol|
|Citation:||JBI Database of Systematic Reviews and Implementation Reports, 2014; 12(8):127-144|
|Publisher:||Joanna Briggs Institute|
|Megan Louise Mathews, Sarahlouise White, Yifan Xue|
|Abstract:||Review objective: The aim of this review is to identify the effects of coenzyme Q10 on women with breast cancer. More specifically, the objective is to identify the effects of coenzyme Q10 on: • Death/survival rate • Standard blood, immune and tumor parameters • Primary and secondary tumors • Recurrence of cancer • Adverse events • Adherence to conventional treatment • Impact on conventional treatment • Measures of quality of life. Inclusion criteria Types of participants: This review will consider studies that include adult women aged 18 years or older who have been managed with conventional treatment (surgery, radiotherapy and/or chemotherapy including hormonal therapy- either alone or in any combination) regardless of type, stage or grade of breast cancer. Types of intervention(s) and comparators: The intervention of interest is coenzyme Q10 therapy following or in addition to conventional treatment (surgery, radiotherapy and/or chemotherapy, including hormonal therapy), either alone or in addition to other nutrients or antioxidants. This study will consider supplementation with coenzyme Q10 regardless of the route or dosage and for a minimum of one week administration. The comparison group is adult women with breast cancer who have had conventional treatment (surgery, radiotherapy and/or chemotherapy, including hormonal therapy). In some study designs there may not be a comparator group and coenzyme Q10 will be considered as an exposure. Types of outcomes: This review will consider the following parameters that indicate increased survival, reduced recurrence and tumor burden, and cancer cure. •Death/survival rate; •Blood concentrations of biochemical markers - standard tests (FBC, EUC, LFT); inflammatory markers erythrocyte sedimentation rate and C-reactive protein 14; tumor markers (CA 15.3, CA 125, CEA) 15; and tumor-related markers (such as but not limited to TNF-alpha, IL2, IL6 and IL8); •Size of primary tumor assessed by ultrasound , mammography, computerized axial tomography, magnetic resonance imaging, positron emission tomography; •Number and size of secondary tumors assessed by ultrasound, chest X-ray, mammography, computerized axial tomography, magnetic resonance imaging or positron emission tomography; •Adverse events resulting from coenzyme Q10; •Adherence to conventional therapy; •Impact of coenzyme Q10 on conventional treatment. This may be either to inhibit, augment or ameliorate actions or adverse events resulting from conventional treatment; and TRUNCATED AT 350 WORDS.|
|Keywords:||Complementary; adjunct; CoQ10; ubiquinone; ubiquinol; mammary carcinoma|
|Rights:||Copyright status unknown|
|Appears in Collections:||Translational Health Science publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.